The FDA accepted vepdegestrant’s new drug software for ER+/HER2–, ESR1-mutated superior breast most cancers with a June 5, 2026, evaluate date: © inventory.adobe.com.
The U.S. Meals and Drug Administration (FDA) has accepted a brand new drug software (NDA) highlighting vepdegestrant for the remedy of sufferers with estrogen receptor-positive (ER+) or human epidermal development issue receptor 2-negative (HER2–), ESR1-mutated superior or metastatic breast most cancers who’ve beforehand obtained endocrine-based remedy, in accordance with a information launch from Arvinas.
As well as, the FDA has assigned a prescription drug person payment act (PDUFA) motion date of June 5, 2026, which is a legislation that requires the FDA to evaluate new most cancers medication inside a set time to assist get remedies to sufferers quicker.
“Sufferers usually face restricted remedy choices after first-line remedy and vepdegestrant demonstrated improved progression-free survival in sufferers with ESR1-mutated ER+/HER2– superior breast most cancers,” John Houston, chairperson, CEO, and president at Arvinas, mentioned within the information launch. “With the efficacy and favorable tolerability seen in VERITAC-2, we imagine vepdegestrant, if accepted, has potential to be a best-in-class remedy choice for sufferers within the second-line ESR1-mutant setting. We sit up for working alongside Pfizer and with the FDA to pursue vepdegestrant’s approval and to make sure this vital remedy choice is made obtainable to sufferers as quickly as attainable.”
The brand new drug software was primarily based on knowledge from VERITAC-2, a world, randomized section 3 scientific trial evaluating vepdegestrant with Faslodex (fulvestrant). These outcomes have been concurrently introduced on the 2025 American Society of Medical Oncology Annual Assembly (ASCO) and revealed in The New England Journal of Medication.
Within the trial, vepdegestrant confirmed a major and significant enchancment in progression-free survival amongst sufferers with estrogen receptor 1 (ESR1) mutations, decreasing threat of development or loss of life by 43% in contrast with Faslodex. Median progression-free survival assessed by blinded impartial central evaluate was 5 months with vepdegestrant versus 2.1 months with Faslodex. Investigator-assessed progression-free survival aligned with these outcomes. The profit was constant throughout all pre-specified subgroups with ESR1 mutations. Nonetheless, within the general intent-to-treat inhabitants, the trial didn’t meet statistical significance for progression-free survival, with a median of three.7 months for vepdegestrant and three.6 months for Faslodex.
Vepdegestrant was typically effectively tolerated within the trial, with a security profile according to earlier research and principally low-grade treatment-emergent negative effects. Charges and severity of gastrointestinal negative effects have been low with vepdegestrant (nausea, 13.5%; vomiting, 6.4%; diarrhea, 6.4%). Grade 4 (life-threatening) negative effects occurred in 5 sufferers (1.6%) receiving vepdegestrant versus 9 sufferers (2.9%) receiving Faslodex. The three most typical negative effects with vepdegestrant have been fatigue (26.6%), elevated alanine transaminase (14.4%) and elevated aspartate aminotransferase (14.4%). Unintended effects resulting in remedy discontinuation occurred in 2.9% of sufferers on vepdegestrant versus 0.7% on Faslodex.
Trial Design and Drug Info
The trial enrolled 624 sufferers at 213 websites in 25 nations, together with 270 with ESR1 mutations. Sufferers have been randomized equally to obtain both vepdegestrant as soon as day by day by mouth on a steady 28-day schedule or Faslodex by injection on Days 1 and 15 of the primary cycle after which on Day 1 of every subsequent 28-day cycle beginning with cycle 2. In complete, 43% of sufferers had ESR1 mutations detected.
The first purpose was to judge progression-free survival in each the mutation-positive group and the general inhabitants, primarily based on a blinded impartial central evaluate. General survival was the important thing secondary endpoint.
Vepdegestrant is an experimental oral treatment designed to interrupt down estrogen receptors, which assist gasoline some breast cancers. It’s being studied as a single remedy choice for sufferers with superior or metastatic breast most cancers that’s estrogen receptor optimistic and HER2 damaging, particularly these whose tumors have mutations within the ESR1 gene and have already obtained prior therapies.
References
- “Arvinas Publicizes FDA Acceptance of the New Drug Utility for Vepdegestrant for the Remedy of ESR1m, ER+/HER2- Superior Breast Most cancers,” Arvinas. Information Launch. August 8.
- “Arvinas and Pfizer’s Vepdegestrant Considerably Improves Development-Free Survival for Sufferers with ESR1-Mutant, ER+/HER2- Superior Breast Most cancers,” Arvinas. Information Launch. Could 31.
For extra information on most cancers updates, analysis and training, don’t overlook to subscribe to CURE®’s newsletters right here.
